ERBB2 and gastric cancer: For example, studies like SOPHIA, NALA, TH3RESA, EMILIA for breast cancer and GATSBY and TyTAN for gastric cancer used other HER2-targeted agents and gained ORR ranged from 16 to 32.8% [2, 15, 34–37].